McKenzie Prillaman is a reporter with The Cancer Letter. She joined the publication in 2024.
Before joining The Cancer Letter, McKenzie was a freelance science and health journalist writing for Nature, Science News, APS News and AARP, among other publications. She earned a master’s degree in science communication from the University of California, Santa Cruz in 2022.
McKenzie previously worked at the Dialogue on Science, Ethics and Religion program of the American Association for the Advancement of Science, and studied adolescent nicotine dependence at the National Institute on Drug Abuse. She graduated from the University of Virginia in 2017 with a bachelor’s degree in neuroscience and a minor in bioethics.
Before joining The Cancer Letter, McKenzie was a freelance science and health journalist writing for Nature, Science News, APS News and AARP, among other publications. She earned a master’s degree in science communication from the University of California, Santa Cruz in 2022.
McKenzie previously worked at the Dialogue on Science, Ethics and Religion program of the American Association for the Advancement of Science, and studied adolescent nicotine dependence at the National Institute on Drug Abuse. She graduated from the University of Virginia in 2017 with a bachelor’s degree in neuroscience and a minor in bioethics.
White House
Source: Livestream of White House Africa Cancer Care ForumThe White House Cancer Moonshot is committing an additional $100 million to programs focused on reducing cancer burden in African countries.
Cancer History Project
Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer.
Kate Choi grew up hearing conversations about skin cancer. Her grandparents had it, as did her cousins.
White House
Leaders of three health agencies presented new initiatives focused on patient-centered research, diversity in clinical trial enrollment, and innovation in clinical research.
The NCI Board of Scientific Advisors approved five new concepts and 17 reissue concepts at a joint meeting of the BSA and the National Cancer Advisory Board June 11-12.
Clinical
Treatment with an indefinite course of osimertinib dramatically improves progression-free survival for patients with stage 3 non-small cell cancer, according to the results of the LAURA trial. The median PFS was 39.1 months in the osimertinib group, compared to 5.6 months with the placebo group.
